Transcatheter Pulmonary Valve Market
Report ID: SQMIG35A3828
Report ID: SQMIG35A3828
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3828 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
143
|Figures:
78
Global Transcatheter Pulmonary Valve Market size was valued at USD 80.0 Million in 2024 and is poised to grow from USD 84.8 Million in 2025 to USD 135.16 Million by 2033, growing at a CAGR of 6.0% during the forecast period (2026-2033).
The primary driver of the global transcatheter pulmonary valve market is the convergence of unmet clinical need for less invasive right ventricular outflow tract therapies and device innovation, which together have reshaped treatment paradigms over the last two decades. Patients with congenital heart disease or inadequate surgical conduits can benefit from transcatheter pulmonary valves, which provide catheter-delivered alternatives and minimal recovery time and risk than repeat open-heart surgery. Success with the Melody valve and its subsequent balloon expandable versions has aided in developing clinicians' willingness to use these devices, leading to regulatory approval, and have helped to build this specialized surgical field into a growing segment of interventional cardiology.
Because mid- and long-term data began to show sustained hemodynamic improvement and lower complication rates compared with reoperation, clinicians expanded indications and hospitals invested in structural heart programs, which accelerated market growth and device refinement. Rising numbers of adults living with repaired congenital defects created a predictable demand for repeat interventions, leading manufacturers to develop lower-profile valves and delivery systems suitable for diverse right ventricular outflow anatomies. With changes to reimbursement models and training at center of excellence facilities continuing to grow, the possibility of widespread adoption of new technology will happen in emerging markets. This will create opportunities for significant volume-based decreases in costs due to real-world collaborative registries validating clinical and economic value.
How is AI Improving Patient Selection and Outcomes in the Transcatheter Pulmonary Valve Market?
AI helps connect imaging technology with simulation to better select patients and improve outcomes in the transcatheter pulmonary valve market. Key aspects include automated CT and echocardiography segmentation that clarifies right ventricular and outflow tract anatomy computer vision that detects subtle anatomic risk factors and machine learning that integrates imaging and clinical data to predict procedural risk. The current state sees tools developed for other transcatheter valves adapted to pulmonary applications and used for device sizing virtual implant simulation and peri procedural planning. These advances help clinicians choose better candidates reduce complications and support more consistent outcomes.
In April 2026, Edwards Lifesciences published three year pooled outcomes from the ALTERRA trials which reinforced device durability and clinical benefit. AI driven imaging and planning tools can help translate those findings into wider adoption by improving candidate matching and reducing procedural uncertainty thereby supporting market growth and efficiency.
Market snapshot - (2026-2033)
Global Market Size
USD 80.0 Million
Largest Segment
Balloon-Expandable Valves
Fastest Growth
Self-Expandable Valves
Growth Rate
6.0% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global transcatheter pulmonary valve market is segmented by product type, procedure type, indication, age group, end user and region. Based on product type, the market is segmented into balloon-expandable valves and self-expandable valves. Based on procedure type, the market is segmented into valve-in-valve procedures and native RVOT procedures. Based on indication, the market is segmented into pulmonary valve stenosis, pulmonary valve regurgitation, congenital heart defects and tetralogy of fallot. Based on age group, the market is segmented into pediatric patients and adult patients. Based on end user, the market is segmented into hospitals, cardiac catheterization laboratories, specialty cardiac centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per the global transcatheter pulmonary valve market growth, balloon-expandable valves segment dominates because clinicians value their predictable deployment mechanics and established clinical outcomes, which reduce procedural uncertainty and streamline operator training. Proven compatibility with familiar delivery systems, clearer regulatory pathways and consistent hemodynamic performance encourage hospital procurement and clinician preference, creating reinforcing adoption across routine and reintervention cases and supporting incremental device refinements that further entrench their clinical role.
However, self-expandable valves are emerging as the most rapidly expanding area due to adaptable frame designs that conform to variable right ventricular outflow tracts and enable treatment of irregular anatomies. Device innovation, growing clinician interest in native anatomies, and development of dedicated delivery tools are accelerating adoption and unlocking new patient cohorts for transcatheter therapy.
Valve-in-valve procedures segment leads because it provides a less invasive option for patients with failing surgical bioprostheses, leveraging predictable anchoring within existing frames and established deployment techniques. That reliability reduces perioperative trauma and recovery burden, aligns with clinician preference for durable, lower risk approaches, and drives institutional adoption, training investment and inclusion in multidisciplinary heart team strategies.
On the other hand, native RVOT procedures are witnessing the strongest growth momentum as developers craft valves and delivery systems to accommodate variable native outflow tracts. Growing clinical evidence and operator experience are enabling percutaneous treatment of congenital and complex anatomies previously handled surgically, creating new indications and expanding the transcatheter patient base.
To get detailed segments analysis, Request a Free Sample Report
Based on the global transcatheter pulmonary valve market sector, North America maintains a leading position in the transcatheter pulmonary valve market due to an integrated combination of clinical expertise, established regulatory frameworks, and concentrated investment in cardiovascular innovation. North America’s mature medical system supports quick acceptance of less invasive valve therapies due to the very high degree of familiarity among interventional cardiologists and pediatric specialists and their resulting experience, which allows for continued refinement of technique. In addition, the widespread use of advanced imaging systems, the abundance of established centers of excellence, and the strong collaboration between both medical device companies and research institutions provide a stimulation of clinical validation and continual improvement of devices through iterations. The presence of organized referral systems and payors also increase patient access for patients with complex congenital or acquired conditions that block blood flow to the lungs from the right side of the heart through the outflow tract thereby supporting the size of the market.
Transcatheter pulmonary valve market in United States benefits from a dense network of tertiary cardiac centers, extensive operator experience, and proactive engagement by device manufacturers in clinical programs. High procedural volumes enable iterative technique refinement and swift dissemination of best practices. Payer coverage frameworks and integrated referral pathways support access for complex congenital and acquired patients, while academic–industry partnerships sustain innovation and post market evidence initiatives that underpin clinician confidence, supply chain reliability.
Transcatheter pulmonary valve market in Canada reflects a concentrated network of specialized cardiac centers and a cautious but supportive reimbursement environment that influences adoption pathways. Regional centers of excellence and training programs support the referral of patients with complex congenital cases; in addition, national registries provide valuable reference sources for practitioners and enhancing their confidence, as well as assist with the dissemination of valve-related technologies.
Based on global transcatheter pulmonary valve regional forecast, rapid expansion across Europe is driven by harmonized clinical practices, growing clinician familiarity with transcatheter approaches, and coordinated efforts to integrate novel therapies into established cardiac care pathways. The generation of evidence accelerates, and there is an increase in peer-to-peer learning. The mechanisms for health technology assessments and the dialogue regarding reimbursement that has been evolving have led to selective adoption of new therapies and technologies at specialist centers. The specialist centers are also acting as centers of excellence, whereby they are sharing the procedural expertise with other centers. Localized manufacturing partnerships and regulatory alignment are removing barriers for new entrants into the market for new therapies and technologies. Emerging training networks and simulation centers further support procedural competency and cross border knowledge transfer.
Transcatheter pulmonary valve market in Germany is characterized by a dense concentration of specialized cardiac centers, robust clinical research infrastructure, and strong collaboration between hospitals and industry. Early technical adoption is enhanced by complex case management and multi-disciplinary heart teams. Health system structures and regional centers will allow for procedural throughput which, in turn, will promote retention of skill and monitor outcomes. National professional societies and academic networks contribute to guideline development and dissemination of best practices.
Transcatheter pulmonary valve market in United Kingdom is distinguished by agile adoption pathways in specialist centers, strong academic clinical trials and growing emphasis on minimally invasive approaches. National referral networks and heart units support concentrated expertise and procedural learning. Communication with payers and bodies responsible for evaluating health technologies will impact access and awareness of providers as well as enhance the volume of referrals to providers through efforts made by patient advocacy groups.
Transcatheter pulmonary valve market in France shows emerging momentum driven by specialized regional centers, growing clinical interest among interventional cardiologists, and targeted collaborations with device innovators. Centralized referral pathways and emphasis on multidisciplinary evaluation guide patient selection. Training initiatives and demonstration programs support clinician uptake in complex congenital structural cases. Increasing dialogue between hospitals and payers, alongside national research networks, nurtures evidence development and cautious scaling of new valve therapies.
As per global transcatheter pulmonary valve regional outlook, Asia Pacific is strengthening its position through targeted investment in interventional cardiology capabilities, expansion of specialist training, and selective local manufacturing partnerships that support device availability. As regional centers work collaboratively with international partners to improve their procedural skill levels, they are increasingly relying on imaging techniques and hybrid operating room systems. The development of our region will be enhanced by the growing emphasis on developing registries and performing pragmatic clinical trials to adapt international clinical literature to patients within our region. The manner in which funding for devices and clinical procedures is being provided to patients is changing, and there is an increase in engagement among providers, payers, and regulators to define the value propositions for these funding pathways. The development of regulatory capabilities and conducting appropriate conversations around reimbursement will improve phased launch opportunities in targeted countries, while local investigator studies will provide information regarding device labeling and clinical procedural protocols.
Transcatheter pulmonary valve market in Japan benefits from advanced imaging infrastructure, a strong base of structural heart specialists, and disciplined regulatory pathways that emphasize rigorous clinical evaluation. The emphasis placed on creating multidisciplinary heart teams and utilising procedural training aids helps healthcare professionals within that field to develop the necessary skills to perform those procedures. Payer engagement and regional centers concentrating complex cases contribute to methodical adoption and accumulation of localized clinical experience.
Transcatheter pulmonary valve market in South Korea is supported by focused investment in cardiovascular technology, numbers of trained interventional specialists, initiatives between clinical centers and device developers. Emphasis on rapid skill acquisition through training programs and international collaborations accelerates procedural confidence. They allow for a concentration of knowledge, experience, and skill in their care of these cases. They seek to work together with the regulatory and payer systems in order to define what evidence is required, not only for assessing a procedure, but also for its eventual realization.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expansion Of Patient Indications
Advances In Valve Materials
High Procedure And Device Costs
Limited Long Term Clinical Evidence
Request Free Customization of this report to help us to meet your business objectives.
Competition in the global transcatheter pulmonary valve market outlook is centered on differentiated platform design, regulatory route and physician adoption, with device-platform pairings and regional approvals shaping share shifts. Large firms pursue platform innovations and targeted acquisitions to secure pipelines while leveraging clinical partnerships to accelerate adoption, as seen in Medtronic’s Harmony clinical rollout, Edwards’ Alterra plus SAPIEN platform use, and Venus Medtech’s VenusP-Valve regulatory expansion.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global transcatheter pulmonary valve industry is propelled by the convergence of unmet clinical need for less invasive right ventricular outflow tract therapies and device innovation, while a second key driver is advances in valve materials and imaging‑guided planning that broaden indications and improve procedural consistency. Growth is tempered by high procedure and device costs that constrain hospital adoption and payer coverage. North America remains the dominant region due to mature clinical programs, robust centers of excellence and supportive reimbursement pathways, and balloon‑expandable valves lead the market because of predictable deployment mechanics, established outcomes and clinician familiarity that simplify procurement and training.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 80.0 Million |
| Market size value in 2033 | USD 135.16 Million |
| Growth Rate | 6.0% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Transcatheter Pulmonary Valve Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Transcatheter Pulmonary Valve Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Transcatheter Pulmonary Valve Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Transcatheter Pulmonary Valve Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Transcatheter Pulmonary Valve Market size was valued at USD 80.0 Million in 2024 and is poised to grow from USD 84.8 Million in 2025 to USD 135.16 Million by 2033, growing at a CAGR of 6.0% during the forecast period (2026-2033).
Competition in the global transcatheter pulmonary valve market is centered on differentiated platform design, regulatory route and physician adoption, with device-platform pairings and regional approvals shaping share shifts. Large firms pursue platform innovations and targeted acquisitions to secure pipelines while leveraging clinical partnerships to accelerate adoption, as seen in Medtronic’s Harmony clinical rollout, Edwards’ Alterra plus SAPIEN platform use, and Venus Medtech’s VenusP-Valve regulatory expansion. 'Medtronic plc', 'Edwards Lifesciences Corporation', 'Abbott Laboratories', 'Boston Scientific Corporation', 'Meril Life Sciences Pvt. Ltd.', 'Venus Medtech (Hangzhou) Inc.', 'Peijia Medical Limited', 'LivaNova PLC', 'MicroPort Scientific Corporation', 'Lepu Medical Technology (Beijing) Co., Ltd.', 'JC Medical, Inc.', 'Foldax, Inc.', 'Colibri Heart Valve LLC', 'Artivion, Inc.', 'Xeltis B.V.', 'JenaValve Technology, Inc.', 'CoreMedic GmbH', 'InnovHeart S.r.l.', 'Balton Sp. z o.o.', 'SMT'
The broadening of clinical indications for transcatheter pulmonary valves increases market growth by enlarging the pool of patients considered suitable for the procedure and by encouraging healthcare providers to integrate this therapy into care pathways. When regulatory approvals and clinical consensus extend use to more anatomical profiles and age groups, hospitals invest in infrastructure and physician training to offer less invasive alternatives. This shift in therapeutic paradigms also fosters payer recognition and updated care guidelines, which together support higher adoption and sustained demand across clinical settings.
Expanded Pediatric And Adult Use: Clinical familiarity and multidisciplinary heart‑team approaches are driving broader adoption across pediatric and adult patients, as physicians gain confidence managing diverse anatomies. Iterative device design and targeted training enable treatment of complex congenital defects and failing surgical valves, while patients seek less invasive alternatives with shorter recovery. Referral networks, center specialization, and manufacturer-sponsored education are expanding procedural access. Payers increasingly emphasize comparative value and real‑world outcomes, supporting guideline updates and referral pathway growth across heterogeneous care settings and adoption momentum.
Why does North America Dominate the Global Transcatheter Pulmonary Valve Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
